

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

| | | | |
|--|--|---|--|
| Licensee 1. Franciscan Alliance, Inc. d/b/a Franciscan Health Dyer 2. 24 Joliet St. Dyer, IN 46311 | | In accordance with letter dated October 04, 2021, 3. License No.: 13-02047-02 is amended in its entirety to read as follows: | 4. Expiration Date: December 31, 2025 5. Docket No.: 030-01602 Reference No.: |
| 6. Byproduct, source, and/or special nuclear material A. Any byproduct material permitted by 10 CFR 35.100 B. Any byproduct material permitted by 10 CFR 35.200 C. Any byproduct material permitted by 10 CFR 35.300 D. Samarium-145 permitted by 10 CFR 35.400 | 7. Chemical and/or physical form A. Any B. Any C. Any D. Sealed Sources (Best Medical International, Inc., Model 2341 to 2345) | 8. Maximum amount that licensee may possess at any one time under this license A. As Needed B. As Needed C. 2 curies total D. 1 curie total | 9. Authorized use A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100. B. For use in imaging and localization studies permitted by 10 CFR 35.200. C. For any use permitted by 10 CFR 35.300. D. For any manual brachytherapy procedure permitted by 10 CFR 35.400. |

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 13-02047-02

Docket or Reference No.:
030-01602

Amendment No. 98

| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form | 8. Maximum amount that licensee may possess at any one time under this license | 9. Authorized use |
|---|---|--|---|
| E. Iodine-125 permitted by 10 CFR 35.400 | E. Sealed Sources (Best Medical International, Inc., Model 2301 to 2316; Theragenics Corporation, Model I-Seed 125.S06) | E. 300 millicuries total | E. For any manual brachytherapy procedure permitted by 10 CFR 35.400. |
| F. Palladium-103 permitted by 10 CFR 35.400 | F. Sealed Sources (Best Medical International, Inc., Model 2331 to 2335; Theragenics Corporation Theraseed, Model 200) | F. 300 millicuries total | F. For any manual brachytherapy procedure permitted by 10 CFR 35.400. |
| G. Any byproduct material permitted by 10 CFR 31.11 | G. Prepackaged Kits | G. 1 millicurie total | G. For use in in-vitro studies. |

CONDITIONS

10. Licensed material shall be used or stored at the licensee's facilities located at Franciscan St. Margaret Health - Dyer, 24 Joliet St., Dyer, Indiana, 46311.
11. The Radiation Safety Officer (RSO) for this license is Marjan Muvceski.
12. Licensed material shall only be used by, or under the supervision of:
 - A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 13-02047-02

Docket or Reference No.:
030-01602

Amendment No. 98

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User (M.D., D.O., etc.)Material and Use

Saud S. Ahmed, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

Ravi S. Bhagwat, M.D.

10 CFR 35.100, 10 CFR 35.200

Richard Dobben, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

Peter John Georgis, M.D.

10 CFR 31.11, 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Perry M. Gilbert, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Gregory Henkle, M.D.

10 CFR 35.100, 10 CFR 35.200

Joseph E. Judge, M.D.

10 CFR 35.100, 10 CFR 35.200

Steven R. Klepac, M.D.

10 CFR 35.100, 10 CFR 35.200

Jong-II Marcus Lee, M.D.

10 CFR 31.11, 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)
10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

Garry Malnar, D.O.

Stephine Marshall, D.O.

10 CFR 35.100, 10 CFR 35.200

Narayan R. Mulamalla, M.D.

10 CFR 35.100, 10 CFR 35.200

Michael A. Nicholas, D.O.

10 CFR 35.100, 10 CFR 35.200

Mark T. Nootens, M.D.

10 CFR 35.100, 10 CFR 35.200

Robert D. Prock, M.D.

10 CFR 35.300, 10 CFR 35.400

Kenneth J. Ramsey, D.O.

10 CFR 35.100, 10 CFR 35.200

Matthew J. Rose, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

Hasrish Shah, M.D.

10 CFR 35.100, 10 CFR 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 13-02047-02

Docket or Reference No.:
030-01602

Amendment No. 98

Authorized User (M.D., D.O., etc.)

Uday Shah, M.D.

Amit D. Vyas, M.D.

Michael A. Wilczynski, D.O.

Ioannis Xenidis, D.O.

Material and Use

10 CFR 35.100, 10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those statements, representations, and procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence impose on the licensee requirements that are more restrictive than or in addition to the regulations.

- A. Application dated June 29, 2015 (ML15188A502)
- B. Letter dated December 10, 2015 (ML15344A465)
- C. Letter dated December 15, 2015 (ML15350A404)
- D. Letter dated July 25, 2017 (ML17223A472)
- E. Letter dated October 31, 2017 (ML17291B049)
- F. Letter dated November 6, 2017 (ML17310B155)
- G. Letter dated October 2, 2018 (ML18284A347)
- H. Letter dated May 7, 2019 (ML19140A298)
- I. Letter dated December 4, 2019 (ML19347D250)
- J. Letter dated January 16, 2020 (ML20022A180)
- K. Letter dated October 29, 2020 (ML20318A184)

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 13-02047-02

Amendment No. 98

Docket or Reference No.:
030-01602

L. Letter dated December 15, 2020 (ML21005A045)

M. Letter dated October 4, 2021 (ML21288A091)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: November 8, 2021By: _____
Sara A. Forster
Region III